Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer
Everett James Moding, Yufei Liu, Barzin Y. Nabet et al. · Nature Cancer · 2020
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple tumor types, but whether further treatment can improve outcomes in patients with MRD is unclear. We applied cancer personalized profiling by deep sequencing (CAPP-Seq) ctDNA analysis to 218 samples from 65 patients receiving chemoradiation therapy for locally advanced non-small-cell lung cancer, including 28 patients receiving consolidation immune checkpoint inhibition (ICI). Patients with undetectable ctDNA after chemoradiation therapy had excellent outcomes whether or not they received consolidation ICI. Among such patients, one died from consolidation ICI-related pneumonitis, highlighting the potential utility of only treating patients with MRD. In contrast, patients with MRD after chemoradiation therapy who received consolidation ICI had significantly better outcomes than patients who did not receive consolidation ICI. Furthermore, the ctDNA response pattern early during consolidation ICI identified patients responding to consolidation therapy. Our results suggest that consolidation ICI improves outcomes for non-small-cell lung cancer patients with MRD and that ctDNA analysis may facilitate personalization of consolidation therapy. Diehn and colleagues report that assaying circulating DNA in patients receiving chemoradiation therapy for non-small-cell lung cancer could identify the patients most likely to benefit from consolidation immunotherapy.
Cited by 365 works. doi:10.1038/s43018-019-0011-0
Authors
- Everett James Moding
- Yufei Liu
- Barzin Y. Nabet
- Jacob J. Chabon
- Aadel A. Chaudhuri
- Angela Bik‐Yu Hui
- Rene F. Bonilla
- Ryan B. Ko
- Christopher H. Yoo
- Linda Gojenola
- Carol D. Jones
- Jianzhong He
- Yawei Qiao
- Ting Xu
- John Victor Heymach
- Anne S. Tsao
- Zhongxing X. Liao
- Daniel Richard Gomez
- Millie Snigdha Das
- Sukhmani Kaur Padda
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- Comprehensive molecular profiling of lung adenocarcinoma
- Comprehensive genomic characterization of squamous cell lung cancers
- Power and sample size calculations
- The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- Integrated digital error suppression for improved detection of circulating tumor DNA